A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination with Temozolomide Versus Temozolomide Alone in Subjects with Metastatic Melanoma
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Veliparib (Primary) ; Temozolomide
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Abbott Laboratories; AbbVie
- 08 Feb 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 13 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Jan 2016, as per ClinicalTrials.gov record.
- 13 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jan 2016, as per ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History